This year’s ASCO seemed to me a remarkable one in terms of clinical findings. Here are some examples, why:
- Good PROSPECTs to de-escalate treatment in rectal cancer: neo-adjuvant radiotherapy may be spared in good chemoresponders according to a large trial piloted by the MSKCC.
- FOLFIRINOX does not seem to benefit as neo-adjuvant treatment for localised pancreatic cancer, according to the phase 2 NorPACT trial.
- You might consider waiting for 2nd line treatment to introduce a CDK4 inhibitor in metastatic breast cancer patients: they seem not to provide significant benefit when introduced earlier in terms of overall survival – and come with the price of higher toxicity as compared with hormonal treatment alone. An important finding of the Dutch academic SONIA trial.
- Your patient’s lung cancer is operable? Check out peri-operative checkpoint inhibition! KEYNOTE-671 randomised adding peri-operative pembrolizumab to peri-operative chemotherapy in non-small cell lung cancer (stages II-IIIB), with a clear benefit in event-free survival at 2 years.
- Are checkpoint inhibitors of little use in ovarian cancer? Maybe not always. In BRCA-naïve ovarian cancers, adding the checkpoint inhibitor to olaparib maintenance seems to improve PFS. Wait: these are interim results of the DUO-O study. But intriguing ones.
Do you share my opinion that this ASCO is a good pick?
You should walk through our congress report to get a broader picture.
Have fun.
Yours, sincerely,
Dr med Stefan Rauh
Biography
Dr Stefan Rauh is currently working as haematooncologist in the oncology department of Centre Hospitalier Emile Mayrisch, Esch, Luxembourg. He is mainly involved in clinical work but also in research and teaching activities and is interested in public policy and international cooperation projects in oncology. He is member of the ESMO Practicing Oncologist’s Working Group since 2011 (chair 2014-2018), member of the ESMO Public Policy Committee, and has been an ESMO Executive Board member in 2015-2016. He is coauthor of the 2017 ESMO European Cancer Patient Coalition (ECPC) Patient Survivorship Guide and an invited expert for the ECPC.
Conflict of Interest Statement: Nothing to declare.
Posted on
Previous Article
« 7-year outcomes of PRODIGE 23 trial Next Article
CARTITUDE-4: Cilta-cel meets expectations in lenalidomide-refractory MM »
« 7-year outcomes of PRODIGE 23 trial Next Article
CARTITUDE-4: Cilta-cel meets expectations in lenalidomide-refractory MM »
Table of Contents: ASCO 2023
Featured articles
Real-world data support new SOC in patients with SCLC
What can real-world evidence teach us about atezolizumab plus bevacizumab in HCC?
Colorectal Cancer
7-year outcomes of PRODIGE 23 trial
Neoadjuvant chemotherapy may be viable option in locally advanced colon cancer
De-escalation of neoadjuvant treatment of locally advanced rectal cancer is non-inferior
Breast Cancer
SONIA: No survival benefit with first-line versus second-line CDK4/6 inhibition in metastatic breast cancer
Adjuvant ribociclib improves invasive DFS in early breast cancer
Gene expression profiles predict benefit of neoadjuvant immune checkpoint therapy in triple-negative breast cancer
Lung Cancer
Adding pembrolizumab to perioperative chemotherapy improves EFS in early-stage NSCLC
TTFields therapy: a new treatment modality for metastatic NSCLC
Adding chemotherapy to EGFR TKI does not improve OS in advanced EGFR-mutated NSCLC
Upper GI Cancer
No improved OS in pancreatic cancer after neoadjuvant mFOLFIRINOX
AI detects gastric cancer with high accuracy in common blood tests
Melanoma
Response-directed treatment personalisation in stage III melanoma
Prognostic and predictive biomarkers in patients with resected stage IIB/C melanoma
GU Cancers
Combining PARP inhibition and androgen receptor-signalling inhibition improves radiographic progression-free survival in HRR-deficient mCRPC
Erdafitinib outperforms chemotherapy in FGFR-altered advanced urothelial cancer
Probiotic CBM588 seems to improve clinical effect cabozantinib/nivolumab in mRCC
Exploratory analysis of IMvigor130 trial finds no OS benefit from atezolizumab in subgroups
Miscellaneous
Immune checkpoint inhibition improves PFS in non-BRCA-mutated ovarian cancer
First-line nivolumab-AVD improves PFS both in adult and paediatric patients with advanced Hodgkin lymphoma
Vorasidenib successfully targets IDH1/2-mutated glioma
ASCO Interviews
IMbrave050: Adjuvant atezolizumab plus bevacizumab provides landmark recurrence-free survival for HCC
What can real-world evidence teach us about atezolizumab plus bevacizumab in HCC?
Related Articles
June 25, 2019
Brain irradiation as treatment option
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy